Alimera Sciences is a global pharmaceutical company focused on retinal health and treatments for retinal diseases.

Alimera Sciences Inc.

Cytokine Challenge

Viewport Meta

IPhone / Mobile Compatible

Euro

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Font API

DNSSEC

WordPress

Amazon

Vice President, General Counsel

Christopher Visick

Co-Founder, Chief Marketing Officer, SVP Corporate Communications and Managed Markets

Dave Holland

Owner

Jitu Rajput

Chief Scientific Officer

Ken Greene

Chief Operating Officer, SVP Commercial Operations Europe

Philip Ashman

Chief Financial Officer

Philip Jones

Director and Audit Committee Chairman

Rick Eiswirth

Vice President Sales

Andy Young

Vice President, Managed Markets

Larry Karner

Vice President, Human Capital

Laura Cegala

Garheng Kong

Frank Torti

Peter J. Pizzo

Mark Brooks

Mary Szela

Brian Halak

Jason Werner

CEO, President & Director

Samer Kaba

Chief Medical Officer

Elliot Maltz

Russell Skibsted

Senior Vice President & Chief Financial Officer

Bryce Youngren

Director

Hedge Fund Funded Companies

East Coast Companies that Exited (Top 10K)

Health Care Companies With More Than 50 Employees (Top 10K)

Health Care Companies With More Than $10M in Revenue (Top 10K)

Alimera Sciences is a pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer. The company is passionate about protecting the retina and developing innovative treatments to preserve vision.

Ocumension Therapeutics

Post-IPO Equity - Alimera Sciences

Federal Government

Post-IPO Debt - Alimera Sciences

Deerfield

Palo Alto Investors

Series C - Alimera Sciences

Series B - Alimera Sciences

Alpharetta

Georgia

United States

North America

Alimera Sciences

Alimera Sciences trading halted, volatility trading pause

Alimera Sciences trading resumes

Alimera Sciences plunges after it sues ANI Pharmaceuticals to close deal

Alimera Sciences GAAP EPS of -$0.06, revenue of $27M

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIM

ANI Pharmaceuticals’ Acquisition of Alimera Sciences

ANI scoops up Alimera, 2 approved ophthalmology meds for $381M-plus

Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal

ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences

An intravitreal implant designed to release fluocinolone acetonide for up to 36 months for the treatment of chronic diabetic macular edema.

Lubricant eye drops developed to provide relief for eye irritation.

Antihistamine eye drops formulated to alleviate symptoms associated with eye allergies.

A program established to ensure business operations comply with legal standards and ethical conduct.

Philippines

Asia

India

Pakistan

Colombia

South America

HTML5

Vimeo

Wordpress

DigiCert

Gravity Forms

Google Fonts

F5 NGINX

Apache Server

Google Analytics

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Alimera Sciences, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 16, 2024 2:41 PM	43d23aae
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 16, 2024 2:41 PM	a0519943
crunchbase trigger	general	Nov 22, 2024 7:44 AM	69d6b35a
crunchbase profile	general	Nov 23, 2024 2:25 AM	6ce49844
li profile	general
translate crunchbase fundingrounds	general	Nov 23, 2024 3:02 AM	049ec76f
peers	general	Oct 16, 2024 2:41 PM	abcf4f06
news basic	general	Oct 16, 2024 2:41 PM	bb60368e
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ALIMERASCIENCES

Alimera Sciences Inc.

Last Close

5.55

13/09 20:00

Market Cap

291.28M

Beta: -

Volume Today

2.68M

Avg: -